Radspherin

DRUG5 trials

Sponsors

Oncoinvent Solutions AS, Oncoinvent AS

Conditions

Carcinomatosis of peritoneal cavityColorectal CarcinomaOvarian CancerPeritoneal CarcinomaPeritoneal Carcinomatosis

Phase 1

Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis

CompletedNCT03732768

Oncoinvent Solutions ASOvarian Cancer, Peritoneal Carcinomatosis

Start: 2020-06-08End: 2025-09-30Updated: 2026-04-17

Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC

CompletedNCT03732781

Oncoinvent ASColorectal Carcinoma, Peritoneal Carcinoma

Start: 2020-05-27End: 2025-05-14Updated: 2025-08-28

Phase 2

A Phase 2, randomised, open label, multicentre study to evaluate efficacy and safety of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in patients with peritoneal carcinomatosis from colorectal carcinoma following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

Not yet recruitingCTIS2023-508496-37-00

Oncoinvent Solutions ASCarcinomatosis of peritoneal cavity

Target: 65Updated: 2025-11-28

A Phase 2, randomised, open label, multicentre study of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are homologous recombination proficient and scheduled to undergo neoadjuvant chemotherapy and interval debulking surgery

RecruitingCTIS2023-508497-28-00

Oncoinvent Solutions ASCarcinomatosis of peritoneal cavity

Start: 2024-06-05Target: 88Updated: 2025-12-04

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

RecruitingNCT06504147

Oncoinvent Solutions ASOvarian Cancer, Peritoneal Carcinomatosis

Start: 2024-06-15End: 2031-02-28Target: 114Updated: 2026-05-20

Related Papers

First experience with intraperitoneal <sup>224</sup>Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer.

2025-12-04

#850 First experience with intra-abdominal 224radium-labelled microparticles (radspherin) after cytoreductive surgery for peritoneal metastasis in recurrent epithelial ovarian cancer (phase 1 study)

2023-09-01

15-month safety and efficacy data after intraperitoneal treatment with <sup>224</sup>Radium-labelled microparticles after CRS-HIPEC for peritoneal metastasis from colorectal cancer.

Journal of Clinical Oncology2023-06-011 citations

First experience with <sup>224</sup>Radium-labeled microparticles (Radspherin®) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study).

2023-03-017 citations